Evaluate

March 12, 2019

ACC 2019 preview – Amarin and Esperion look for an edge

Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.

March 19, 2018

Interview – Dalcor’s Hail Mary pass spirals toward the end zone

October 27, 2017

Snippet roundup: CETP kaput and Biogen buys into amyloid

October 13, 2017

Snippet roundup: The FDA says no to Acelrx whereas Merck decides not to ask

August 29, 2017

ESC 2017 – Merck still won’t Reveal its hand

January 19, 2017

Event – Merck awaits news on free win with high risk heart drug

December 09, 2016

CTAD – Over and out for sola, while Biogen takes the spotlight

November 24, 2016

Kymab joins the $100m club

October 18, 2016

Biotech venture funding shrinks as post-boom shape emerges